SCHEMBL329298

SCHEMBL329298

CC(=O)Oc1ccc(Cl)cc1C(=O)O

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFD P00746 2/20 0.69
KDM4E B2RXH2 6/20 0.58
TSHR P16473 5/20 0.58
ALDH1A1 P00352 5/20 0.58
HSD17B10 Q99714 4/20 0.58
HPGD P15428 3/20 0.58
PTGS1 P23219 2/20 0.58
PTGS2 P35354 2/20 0.58
ESR1 P03372 1/20 0.58
ITGB3 P05106 1/20 0.58
ITGA2B P08514 1/20 0.58
HMGB1 P09429 1/20 0.58
GGT1 P19440 1/20 0.58
BLM P54132 1/20 0.58
NAPRT Q6XQN6 1/20 0.58
TDP1 Q9NUW8 1/20 0.58
GAA P10253 3/20 0.54
TP53 P04637 1/20 0.53
CA1 P00915 1/20 0.52
CA2 P00918 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3691064 0.87 KMT2A (0.61) CFDKDM4ETSHRALDH1A1HSD17B10
SCHEMBL239981 0.86 CFD (0.50) CFDKDM4ETSHRALDH1A1HSD17B10
SCHEMBL1316498 0.86 KDM4E (0.67) CFDKDM4ETSHRALDH1A1HSD17B10
Hydrochloric Acid SCHEMBL8205451 0.84 KDM4E (0.65) CFDKDM4ETSHRALDH1A1HSD17B10
SCHEMBL30472752 0.84 KDM4E (0.51) CFDKDM4ETSHRALDH1A1HSD17B10
SCHEMBL330287 0.83 TSHR (0.51) CFDKDM4ETSHRALDH1A1HSD17B10
SCHEMBL7414042 0.83 ABL1 (0.54) CFDKDM4EALDH1A1TDP1GAA
SCHEMBL48961 0.81 MRGPRX4 (0.64) KDM4ETSHRALDH1A1HPGDTDP1
SCHEMBL30100412 0.81 MRGPRX4 (0.64) KDM4ETSHRALDH1A1HPGDTDP1
SCHEMBL16715329 0.81 CFD (1.00) CFDKDM4ETSHRALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8048896-B2 Inhibit nonenzymatic formation of advanced glycation end-products (AGE) using e.g. aminoguanidine, OPB-9195 [(+/-)-2-isopropylidenehydrazono-4-oxo-thiazolidin-5-yla cetanilide], pyridoxamine, antioxidants, alagebrium, antihypertensives, angiotensin-converting enzyme inhibitors Cell Viable Corporation (US) 2011-11-01 US claimed
EP-1165064-B1 NOVEL INHIBITORS OF FORMATION OF ADVANCED GLYCATION ENDPRODUCTS (AGE'S) HOPE CITY (US) 2004-02-25 EP claimed
US-6337350-B1 CROSSLINKING INHIBITION OF PROTEINS CITY OF HOPE 2002-01-08 US claimed
EP-1165064-A2 NOVEL INHIBITORS OF FORMATION OF ADVANCED GLYCATION ENDPRODUCTS (AGE'S) City of Hope (US) 2002-01-02 EP claimed
WO-2000059875-A2 NOVEL INHIBITORS OF FORMATION OF ADVANCED GLYCATION ENDPRODUCTS (AGE'S) CITY OF HOPE (US) 2000-10-12 WO claimed
US-5985927-A Medicaments for the selective treatment of tumor tissues KREUTZ WERNER (DE) 1999-11-16 US claimed
CN-116283752-A N-heteroaryl-5-chlorosalicylamide compound, preparation method thereof and application thereof in resisting tubercle bacillus 中山大学 2023-06-23 CN disclosed
EP-1372615-B1 COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS EMISPHERE TECH INC (US) 2013-04-24 EP disclosed
US-8273794-B2 7-[isopropyl(phenyl)amino]-7-oxoheptanoic acid, 3-(2-Hydroxy-benzoylamino)-butyric acid, 4-Oxo-4-phenyl-butyric acid, 10-(2-Hydroxy-phenyl)-10-oxo-decanoic acid, 4-(4-Methoxy-phenyl)-4-oxo-butyric acid: promoting the absorption of the active agent EMISPHERE TECHNOLOGIES, INC. (US) 2012-09-25 US disclosed
US-8263657-B2 Blocking neurokinins; using a benzene compound containing hydroxy or acetoxy group; antiinflammatory agents INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2012-09-11 US disclosed
US-8097759-B2 Inflammatory cytokine release inhibitor INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2012-01-17 US disclosed
US-8053449-B2 Method for inhibiting AGE complex formation Cell Viable Corporation (US) 2011-11-08 US disclosed
US-8048896-B2 Inhibit nonenzymatic formation of advanced glycation end-products (AGE) using e.g. aminoguanidine, OPB-9195 [(+/-)-2-isopropylidenehydrazono-4-oxo-thiazolidin-5-yla cetanilide], pyridoxamine, antioxidants, alagebrium, antihypertensives, angiotensin-converting enzyme inhibitors Cell Viable Corporation (US) 2011-11-01 US disclosed
US-6337350-B1 CROSSLINKING INHIBITION OF PROTEINS CITY OF HOPE 2002-01-08 US disclosed
WO-2000076971-A2 SERINE PROTEASE INHIBITORS ELI LILLY AND COMPANY (US) 2000-12-21 WO disclosed
WO-2000076970-A2 SERINE PROTEASE INHIBITORS ELI LILLY AND COMPANY (US) 2000-12-21 WO disclosed
US-5985927-A Medicaments for the selective treatment of tumor tissues KREUTZ WERNER (DE) 1999-11-16 US disclosed
US-4146631-A ANTIALLERGENS, RESPIRATORY DISORDERS MAY & BAKER LIMITED (GB) 1979-03-27 US disclosed
US-4024160-A Substituted 2-amino chromones and process for the preparation thereof WARNER-LAMBERT COMPANY (US) 1977-05-17 US disclosed
US-3932466-A Substituted 2-amino chromones and process for the preparation thereof WARNER-LAMBERT COMPANY (US) 1976-01-13 US disclosed